Mr. Murray established BV Murray & Co. Inc., a boutique investment bank in 1996 after 17 years at Bear Stearns in the corporate finance department where he was a Senior Managing Director. Prior to joining Bear Stearns in 1978, he was a partner at HC Wainwright & Co, an institutional Wall Street research firm. Over his career, Mr. Murray has obtained extensive worldwide experience in mergers and acquisitions, valuations and public and private debt and equity of offerings. Mr. Murray holds a B.S. degree in Economics from Villanova University, an MBA with honors (majoring in finance and international business) from the University of Chicago and is a Chartered Financial Analyst (“CFA”).

Dr. Chan is the CEO and President of CytoSorbents Corporation (CTSO-NASDAQ), a leader in critical care immunotherapy, specifically leading in the prevention and treatment of life-threatening inflammation using the patented CytoSorb Blood Purification device. Prior to CytoSorbents, he led healthcare and life science investments as a Partner for the NJTC Venture Fund. In that role, he was responsible for numerous investments in therapeutics, medical devices and diagnostics. Phil also co-founded Andrew Technologies as an early and lead investor. He received Board-certification in internal medicine, completing his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. He received his MD/PhD from Yale University School of Medicine and his BS in Cell and Molecular Biology from Cornell University. Dr. Chan is also a member of Medality’s Medical and Scientific Committee.

Dr. Andrew is the Founder and Chief Scientific Officer. He is the co-inventor of Targeted Cell Separation and Extraction Technology TC-SET™ Medality Medical’s HydraSolve® is the second clinical application of TC-SET™, the first being the AquaLase® Liquefaction Device, a small-incision cataract removal technology on Alcon’s premier cataract machine, the INFINITI® Vision System, used routinely in more than 50 countries. Dr. Andrew, a Fellow of the American Academy of Ophthalmology, is a board-certified ophthalmologist with more than 25 years of experience. He received his medical degree from Jefferson Medical College (Sidney Kimmel Medical College) in Philadelphia, PA, and served his residency at Hahnemann University Hospital in Philadelphia. His scientific background includes basic science research in biochemistry, endocrinology, and immunology, as well as research in fluid dynamics at the National Eye Institute of the National Institutes of Health (NIH), Drexel University School of Biomedical Engineering, Jefferson Medical College (Sidney Kimmel Medical College), Wills Eye Hospital and the Penn State Health Milton S. Hershey Medical Center. Dr. Andrew holds 10 issued US patents, and 27 issued foreign patents, with more pending. Dr. Andrew’s inventions have led to 6 FDA clearances, 25 peer-reviewed journal articles, and numerous surgical textbook citations.

Dr. D’Amico is the Assistant Clinical Professor of Plastic Surgery Mt Sinai School of Medicine in New York. Dr. D’Amico is an internationally published and recognized leader in Plastic Surgery and its cutting edge technologies and innovations. He received his medical degree from the New York University School of Medicine and completed his plastic surgery fellowship at Columbia Presbyterian Medical Center in New York City. Dr. Richard D’Amico holds membership in many professional groups, which comprise an important part of his career. The American Society for Aesthetic Plastic Surgery (ASAPS), the American Society of Plastic Surgeons (ASPS), the American Cleft Palate-Craniofacial Association, the Lipoplasty Society of North America, the New York Regional Society of Plastic and Reconstructive Surgeons, and the American Medical Association all count Dr. Richard D’Amico among their members. Another group, the American College of Surgeons, granted a fellowship to Dr. Richard D’Amico. Many of these organizations have appointed Dr. Richard D’Amico to significant positions. In 2008, the ASPS elected Dr. Richard D’Amico as its President, and he still serves on its Executive Committee and Board of Directors. The New Jersey Society of Plastic Surgeons also picked Richard D’Amico to serve as President in the past. Dr. Richard D’Amico additionally sits on the Board of Directors for the American Association for Accreditation of Ambulatory Surgical Facilities, the Innovative Technology Committee for the American Society for Aesthetic Plastic Surgery, and the Medical Expert Advisory Panel for the New Jersey State Board of Medical Examiners. Additionally, Dr. Richard D’Amico co-chaired the ASPS’ Breast Implant Task Force, participated in its Committee to Set Standards of Care for procedures such as liposuction and blepharoplasty, and functioned as Vice Chairman of its Government Relations Committee. He is currently a medical advisor to several medical device companies.

Mr. Horsburgh has spent the majority of his career in the financial services industry, starting in institutional equity sales with Hoare Govett, a leading firm of UK stockbrokers. He moved in 1976 to Bear Stearns and Co. in the US, where he spent 15 years and was a General Partner. While there, he was actively involved in the creation of a number of publicly-traded closed-end and privately-placed investment funds, of which he was also a Director; he was also Chairman of Bear Stearns’ International Committee. Following this, he founded Horsburgh Carlson Investment Management, a US boutique asset management company, which he subsequently sold to his partners at Carlson Investment Management. From 2007-2021, Mr. Horsburgh was involved in investing in the hedge fund industry with Arden Asset Management, where he was a partner. Arden was sold to Aberdeen Asset Management, which subsequently merged with Standard Life – both Scottish-based global investment management companies. He retired from Aberdeen Standard in 2021. Mr. Horsburgh graduated from the Royal Military Academy, Sandhurst, serving in the British Army for six years, during which time he saw combat in the Far East.

Dr Levine is an investment banker with over 30 year’s experience in multiple cross-border financial transactions, including privatizations, project finance, M&A, private and public debt, and equity capital offerings. He was engaged in senior management roles in Donau Bank and Bank Winter AG in Vienna and Petroleum Investment Management in London. Currently Dr Levine is Managing Partner of BVM Capital Partners Ltd., a London based boutique investment banking firm, and is also holding non-executive independent board memberships in the London Stock Exchange listed public oil and petrochemical company Tatneft (as chairman of the audit committee); in Ak Bars Bank, Kazan, Tatarstan (as chairman of the risk committee and member of the audit committee); and in Winter Finanz AG, Switzerland. Prior to investment banking Dr Levine pursued academic career in international economic research in Moscow based “think tank” IMEMO (Institute of World Economy & International Relations). Dr Levine holds master’s degrees in Economics, Finance & Banking with honors from Moscow Finance Academy, and received Ph.D. in Economics after three-year post graduate program in International Trade and Finance in IMEMO and one-year post graduate exchange program in International Economics at Stanford Research Institute (SRI), California.